

MARCH 21 - 24, 2018 · HILTON ORLANDO · ORLANDO, FL

SYMPOSIUM

Innovation in Clinical Dose Selection and Trial Optimization Using Bayesian Approaches: Steps Toward Accelerated Patient Care

Pharmacometrics & Pharmacokinetics (PMK)
Regulatory Science (RS)

Chair: Indrajeet Singh, PhD


Janssen Pharmaceuticals, Spring House, PA

Chair: Ying Ou, PhD

Amgen, South San Francisco, CA

SATURDAY, MARCH 24, 2018 1:15 PM – 3:15 PM

Innovation is long due



Total Failures (%)	Ph-II (2008 → 2015)	Ph-III (2008 → 2015)	
Efficacy	51 → 48	66 → 55	
Safety	19 → 25	21 → 14	
Efficacy + Safety	70 → 73	87 → 69	

Patients are waiting



Presentations

- Bayesian Statistics and Its implications for Drug Development Stephen Ruberg, PhD
 Eli Lilly, Indianapolis, IN
- Bayesian Adaptive Trials in Oncology Drug Development–Maximizing the Synergy Between Statisticians and Clinical Pharmacologists Stuart Bailey, PhD Novartis, Cambridge, MA
- Challenges and Opportunities of Bayesian Adaptive Trials:
 Regulatory and Pharmacometrics Perspectives
 Yaning Wang, PhD
 US Food and Drug Administration, Silver Spring, MD
- Challenges and Opportunities of Bayesian Adaptive Trials: Where Do We Go From Here?

 Carl C. Peck, MD
 - UCSF Center for Drug Development Science, San Luis Obispo, CA